Top 5 Tech Stocks To Invest In Right Now

Click the chart to track GSV Capital.

NEW YORK (CNNMoney) Twitter is officially on the road to a stock market debut, and funds that already own stakes in the social media company are enjoying the ride.

Shares of GSV Capital (GSVC), a publicly traded fund that invests in "high growth" private companies, rallied almost 13% Friday. GSV said it holds 1.9 million shares of Twitter as of June 30. Twitter is the fund's biggest holding, at 15% of the total portfolio.

Similarly, Twitter is also the biggest holding in the Firsthand Technology Value Fund (SVVC). With just over 1 million shares of the social media platform, Twitter represents nearly 11% of the total portfolio as of mid-year. Shares of Firsthand Technology Value jumped more than 6% Friday.

Both funds, which owned Facebook (FB) prior to its market debut and remain invested in that company, ran up significantly last year before Facebook's highly anticipated IPO. Both tumbled in the aftermath of Facebook's botched debut on the Nasdaq. But the funds have rebounded recently thanks to the recovery in Facebook's stock.

Top 5 Gas Utility Stocks To Own For 2015: Convergys Corporation (CVG)

Convergys Corporation provides relationship management solutions in North America and internationally. Its Customer Management segment offers agent-assisted, self-service, and intelligent technology care solutions, including customer service, customer retention, sales, technical support, social interaction, collections management, back office, business-to-business, customer experience applied analytics, and intelligent interaction solutions for communications, financial services, technology, retail, healthcare, and government markets. This segment also provides premise-based and hosted automated self-care and technology solutions; speech recognition solutions; and license, professional, consulting and maintenance, and software support services. Convergys Corporation was founded in 1998 and is headquartered in Cincinnati, Ohio.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Convergys (NYSE: CVG) was also up, gaining 12.44 percent to $23.46 after the company announced its plans to acquire Stream Global Services for $820 million in cash. Convergys also reaffirmed its outlook for 2013.

Top 5 Tech Stocks To Invest In Right Now: AU Optronics Corp (AUO)

AU Optronics Corp. engages in the design, development, manufacture, assembly, and marketing of thin film transistor liquid crystal displays and other flat panel displays. The company operates in two segments, Display and Solar. It offers a range of display panels for use in mobile PCs, such as notebooks and tablets; desktop monitors; consumer electronics products consisting of mobile phones, digital still cameras, portable navigation displays, digital camcorders, automobile displays, amusement and printer displays, and portable gaming consoles; and LCD televisions. The company sells its panels to original equipment manufacturing service providers who manufacture products on a contract basis for brand companies; and to brand companies on a direct shipment basis. It also manufactures upstream and midstream products, such as polysilicons, ingots, wafers, and solar cells; designs, develops, and manufactures solar photovoltaic (PV) modules; produces solar PV systems; and provid es various value-added services for solar PV systems projects. AU Optronics Corp. operates in the People�s Republic of China, Taiwan, Singapore, Korea, and internationally. The company was formerly known as Acer Display Technology, Inc. and changed its name to AU Optronics Corp. in May 2001. AU Optronics Corp. was founded in 1996 and is based in Hsinchu, Taiwan.

Advisors' Opinion:

• [By Seth Jayson]

  Basic guidelines
  In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at AU Optronics (NYSE: AUO  ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is AU Optronics doing by this quick checkup? At first glance, pretty well. Trailing-12-month revenue increased 6.5%, and inventory decreased 13.1%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue increased 14.9%, and inventory contracted 13.1%. Over the sequential quarterly period, the trend looks worrisome. Revenue dropped 7.7%, and inventory grew 7.7%.

• [By Monica Gerson]

  AU Optronics (NYSE: AUO) shares reached a new 52-week low of $3.06. AU Optronics' PEG ratio is 2.34.

  CBL & Associates Properties (NYSE: CBL) shares fell 5.20% to reach a new 52-week low of $18.43 after the company reported Q3 results.

Top 5 Tech Stocks To Invest In Right Now: Epizyme Inc (EPZM)

Epizyme, Inc., incorporated on November 1, 2007, is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers. The Company systematically identify the genetic alterations that create cancer causing genes, called oncogenes, select patients in whom the identified genetic alteration is found and then design small molecule therapeutics to inhibit the oncogene. The clinical development plan for each of its product candidates is directed towards patients with a particular genetically defined cancer.The Company is conducting a Phase I clinical trial of its advanced product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT, for the treatment of mixed lineage leukemia (MLL-r). The Company has identified its two lead product candidates using its product platform.

EPZ-5676-DOT1L Inhibitor

EPZ-5676 is an intravenously administered small molecule inhibitor of DOT1L. The Company is developing EPZ-5676 for the treatment of MLL-r, an aggressive subtype of the two most common forms of acute leukemia, ALL and AML. Patients with MLL-r are routinely diagnosed with existing technologies that are commonly used in clinical setting. The Company�� Phase 1 clinical trial of EPZ-5676 is an open label, multicenter trial that has two phases.

EPZ-6438-EZH2 Inhibitor

The Company is developing EPZ-6438 as an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients who have an oncogenic point mutation in EZH2. EZH2 is an HMT that can become oncogenic and cause non-Hodgkin lymphoma and a range of other solid tumors. Two types of non-Hodgkin lymphoma, diffuse large B-cell lymphoma of germinal-center origin, or DLBCL, and follicular lymphoma, or FL, are particularly associated with an EZH2 point mutation. There are no therapies approved specifically for the treatment of cancer associated with an EZH2 point mutation.

Advisors' Opinion:

• [By John Udovich]
  Follow-on Stock Offerings From Small Cap Biotech Stocks. Thanks to the boom in biotech IPOs along with the sector�� overall performance, already listed biotechs have the option to ask investors for more cash in the form of a follow-on offering. Recently, FierceBiotech.com noted how four small cap biotechs raised $276 million from follow-on offerings in just one day last week. These small caps�included Epizyme Inc (NASDAQ: EPZM) which raised $88 million, Halozyme Therapeutics, Inc (NASDAQ: HALO) which raised $100 million, Agenus Inc (NASDAQ: AGEN) which raised $52 million and Idera Pharmaceuticals Inc (NASDAQ: IDRA) which raised $36 million. FierceBiotech.com noted that the�steady flow of about $4.5 billion a year in venture cash�along with�more than $3.5 billion from IPOs last year plus all of the�follow-ons are helping to foster both company growth and�accelerate drug�development programs. Mixed Bag for Biotech IPOs. Last Wednesday also saw two small cap biotech IPOs fizzle in one day�with small cap T cell vaccine developer�Genocea Biosciences Inc (NASDAQ: GNCA) raising $60 million but then ending the day down 8.3% to close at $11 while Dutch drug developer uniQure NV (QURE) raised $81.9 million but fell more than 14% to $14.61. However, orphan drug stock Auspex Pharmaceuticals Inc (NASDAQ: ASPX), which is developing�drugs to treat orphan diseases like Tourette syndrome, saw a 30.5% gain to close at $15.66 and raise $84 million. The Boston Globe quoted Michael Ringel, a partner and managing director at Boston Consulting Group who focuses on health care business, as saying:

  ��he mood is incredibly positive. Capital is flowing. [The biotech IPOs]��have been burning hot. I think it�� too early to suggest that is changing. I can�� predict the overall economy any better than anyone else, but I would expect a pretty good year for IPOs.��/p>

• [By Laura Brodbeck]

  Friday

  Earnings Expected From: Epizyme (NASDAQ: EPZM), Dyax Corp (NASDAQ: DYAX) Economic Releases Expected: ��German GDP, German business climate index, Italian retail sales.

  Get all the #premarket info by listening in to Benzinga's morning show at 8:00 am EST Monday-Friday!

• [By Lisa Levin]

  Epizyme (NASDAQ: EPZM) shares rose 66.84% to $34.20. The volume of Epizyme shares traded was 1683% higher than normal. Epizyme reported two major milestone achievements. It announced the achievement of a proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program.

• [By John Udovich]

  It�� a new year and the first one and a half trading weeks of 2014 has not disappointed biotech investors as the sector and mid cap or small cap biotech or�pharma stocks like Intercept Pharmaceuticals Inc (NASDAQ: ICPT), Epizyme Inc (NASDAQ: EPZM), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and TNI BioTech Inc (OTCQB: TNIB) either surging or producing some news plus there have been IPO filings for future listings for�Flexion Therapeutics (NASDAQ: FLXN), Aldexa Therapeutics (NASDAQ: ALDX), Retrophin (NASDAQ:�RTRX) and Dicerna Pharmaceuticals (NASDAQ: DRNA). Consider the following news so far this year:

Top 5 Tech Stocks To Invest In Right Now: TomTom NV (OEM)

TomTom NV is a Netherlands-based supplier of location and navigation products and services. The Company�� structure consists of four customer facing business units, namely Consumer, Automotive, Business Solutions and Licensing. The first three business units provide targeted solutions for the Company�� customers, including private consumers, car manufacturers and fleet owners. Licensing sells its content and services to multiple customer groups including portable navigation devices (PNDs) and wireless companies, governments and enterprises. The Company�� business units embed 11 product units, such as digital maps, traffic intelligence, navigation software, PNDs, automotive systems, fleet management services (FMS), smart phone applications, sports watches, points of interest, location based services (LBS) and speedcam intelligence. As of December 31, 2011, the Company was active in 35 countries. In July 2013, it acquired Coordina (Gestion Electronica Logistica, S.L.). Advisors' Opinion:

• [By victorselva]

  In a macro view, revenues in the electronic equipment and instrument sub-industry will remain strong due to the rise in equipment and instrument manufacturers. Distributors, electronic manufacturing service (EMS) companies and original equipment manufacturers (OEM) are going to increase orders as the economy improves in the future. With this promising outlook, let's take a look at Gabelli麓s last trade and try to explain to investors the reasons of this appealing investment opportunity.

• [By ICRAOnline]

  In the previous three-month period (fourth quarter), revenue fell 4% year over year to $1.65 billion mainly on account of 33.7% drop in original equipment manufacturer (OEM) revenues and 0.8% decline in branded revenues. Product revenues dropped 8.4%, which was partially compensated by 8% improvement in service revenues.